Proteomics of endometrial cancer diagnosis, treatment, and prognosis

Mittal, Parul; Klingler‐Hoffmann, Manuela; Arentz, Georgia; Zhang, Chao; Kaur, Gurjeet; Oehler, Martin K.; Hoffmann, Peter

doi:10.1002/prca.201500055

Cited by 22 publications

(19 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increased level of hCG after evacuation of the hydatidiform mole (HM) indicates that there is underlying GTN, yet before there is any hCG increase, we are unable to determine which women will require systemic chemotherapy. Clinical proteomics is a systems approach that facilitates the discovery of novel markers [2]. One of the first reports on proteomics in oncology demonstrated the possibility of using two-dimensional gel electrophoresis (2-DE) to analyze protein-bound fucose in cancer sera [13].…”

Section: Discussionmentioning

confidence: 99%

“…Protein biomarkers, such as human chorionic gonadotropin β (βhCG), carbohydrate antigen 125 (CA 125), and human epididymis protein 4 (HE4), are already used in the field of gynecologic oncology [1]. Proteomics is a promising method for discovering protein profiles and increasing the sensitivity and specificity of biomarkers that are currently in use [2].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MALDI-TOF-MS Analysis in the Identification of Urine Proteomic Patterns of Gestational Trophoblastic Disease

et al. 2019

View full text Add to dashboard Cite

Gestational trophoblastic disease (GTD) is a group of highly aggressive, rare tumors. Human chorionic gonadotropin is a common biomarker used in the diagnosis and monitoring of GTD. To improve our knowledge of the pathology of GTD, we performed protein-peptide profiling on the urine of patients affected with gestational trophoblastic neoplasm (GTN). We analyzed urine samples from patients diagnosed with GTN (n = 26) and from healthy pregnant and non-pregnant controls (n = 17) using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Ions were examined in a linear mode over a m/z range of 1000–10,000. All GTN urine samples were analyzed before and after treatment and compared with those of the controls. The statistical analyses included multivariate classification algorithms as well as ROC curves. Urine sample analyses revealed there were significant differences in the composition of the ions between the evaluated groups. Comparing the pre-treatment and group with the pregnant controls, we identified two discriminatory proteins: hemoglobin subunit α (m/z = 1951.81) and complement C4A (m/z = 1895.43). Then, comparing urine samples from the post-treatment cases with those from the non-pregnant controls, we identified the peptides uromodulin fragments (m/z = 1682.34 and 1913.54) and complement C4A (m/z = 1895.43).

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

MALDI-TOF-MS Analysis in the Identification of Urine Proteomic Patterns of Gestational Trophoblastic Disease

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Many cancers are curable if they are detected sufficiently early, however most existing blood‐based cancer screening tests, such as PSA and CA‐125, lack sensitivity and reliability for the early diagnosis of cancer. Many studies have attempted to identify diagnostic biomarkers in the blood using a variety of sophisticated proteomic technologies . However, the biochemical makeup of blood is very complex and variable, making it extremely difficult to identify low abundance tumor‐specific proteins, including tumor antigens, and none of the protein biomarkers identified so far are currently in clinical use for detection of early cancer.…”

Section: Clinical Utility Of Tumor Antigens and Antitumor Antibodiesmentioning

confidence: 99%

“…Many studies have attempted to identify diagnostic biomarkers in the blood using a variety of sophisticated proteomic technologies. [68][69][70] However, the biochemical makeup of blood is very complex and variable, making it extremely difficult to identify low abundance tumor-specific proteins, including tumor antigens, and none of the protein biomarkers identified so far are currently in clinical use for detection of early cancer.…”

Section: Early Diagnosis Of Cancermentioning

confidence: 99%

Secreted Tumor Antigens – Immune Biomarkers for Diagnosis and Therapy

Meeusen

Lim

2017

Proteomics

View full text Add to dashboard Cite

With the advent of immunotherapies for cancer, there is growing interest in the identification of tumor antigens. Tumor antigens are self-molecules altered through e.g. genetic mutations (neoantigens), protein truncation, protein misfolding, or abnormal posttranslational modifications. To induce an immune response, tumor antigens need to be secreted into the tumor environment and presented to the immune system in the draining lymph nodes, resulting in the generation of tumor-specific effector cells and antibodies. Cytotoxic T cells are thought to be responsible for killing of tumor cells, and several recent studies have used MS, combined with exome/transcriptome sequencing and bioinformatics, to identify their cognate peptide ligands on tumor MHC class I molecules. Circulating (serum) antibodies have been more widely used to identify tumor antigens in a range of human cancers, using 2D Western blots, immunoaffinity, and microarray technologies. More specific antibody probes have been generated by harvesting antibodies directly from antibody-secreting cells through in vitro cultures of lymph node cells (antibody-secreting cells probes) or B-cell immortalization. Further identification and characterization of tumor antigens is likely to have important implications for cancer diagnostic and biomarker discovery, immune profiling, and the development of cancer vaccines and targeted immunotherapies.

show abstract

“…Recently, we have shown the capacity of MALDI‐MSI to discriminate regions of healthy endometrial tissue from tumour . Here we present an analysis of primary EC specimens with ( n = 16) and without LNM ( n = 27) by MALDI‐MSI.…”

Section: Introductionmentioning

confidence: 99%

Lymph node metastasis of primary endometrial cancers: Associated proteins revealed by MALDI imaging

et al. 2016

Self Cite

View full text Add to dashboard Cite

Metastasis is a crucial step of malignant progression and is the primary cause of death from endometrial cancer. However, clinicians presently face the challenge that conventional surgicalpathological variables, such as tumour size, depth of myometrial invasion, histological grade, lymphovascular space invasion or radiological imaging are unable to predict with accuracy if the primary tumour has metastasized. In the current retrospective study, we have used primary tumour samples of endometrial cancer patients diagnosed with (n = 16) and without (n = 27) lymph node metastasis to identify potential discriminators. Using peptide matrix assisted laser desorption/ionisation mass spectrometry imaging (MALDI-MSI), we have identified m/z values which can classify 88% of all tumours correctly. The top discriminative m/z values were identified using a combination of in situ sequencing and LC-MS/MS from digested tumour samples. Two of the proteins identified, plectin and ␣-Actin-2, were used for validation studies using LC-MS/MS data independent analysis (DIA) and immunohistochemistry. In summary, MALDI-MSI has the potential to identify discriminators of metastasis using primary tumour samples.

show abstract

Proteomics of endometrial cancer diagnosis, treatment, and prognosis

Cited by 22 publications

References 96 publications

MALDI-TOF-MS Analysis in the Identification of Urine Proteomic Patterns of Gestational Trophoblastic Disease

MALDI-TOF-MS Analysis in the Identification of Urine Proteomic Patterns of Gestational Trophoblastic Disease

Secreted Tumor Antigens – Immune Biomarkers for Diagnosis and Therapy

Lymph node metastasis of primary endometrial cancers: Associated proteins revealed by MALDI imaging

Contact Info

Product

Resources

About